• EN
  • FR
  • Disease areas
  • Products
  • Science & technology
  • Sustainable business
  • Careers
  • About us
  • Patient help
  • Insulin 100
  • News & media
  • Contact us

Health Canada approves REBINYN® for the treatment of routine prophylaxis to prevent or reduce frequency of bleeding episodes in children... 2022.10.26
Creation of a National Training Program for Healthcare Professionals Involved in Obesity Prevention and Care 2022.04.05
Novo Nordisk expands product offerings in Canada for the treatment of Hemophilia A in both children and adults, with availability of ESPEROCT® and ZONOVATE® 2022.04.01
   

Health Canada approves Wegovy™ for the treatment of adults with obesity 2021.11.25
Health Canada approves Norditropin NordiFlex® - first approved human growth hormone treatment for Noonan syndrome in Canada
2021.06.25
Continued Support for Banting and Best’s Insulin Discovery and Research at the University of Toronto
2021.04.12
Health Canada approves Saxenda® (liraglutide injection) for the treatment of obesity in adolescents aged 12- <18 2021.03.03
Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention  2021.02.24

Camp Huronda receives $1.5M donation to rebuild on-site medical centre

 2021.01.14
Camp Huronda infographic                                                                                                                                                     2021.01.14

Novo Nordisk Canada Inc.

101-2476 Argentia Road
Mississauga, Ontario L5N 6M1
Phone: +1-905-629-4222
Phone (Toll-free): +1-800-465-4334
Fax: +1-905-629-8662
Fax (Toll-free): +1-844-465-2225

Helpful links

Contact us

Follow us

LinkedIn Facebook Twitter Instagram

Other offices

Select country
© 2023 Novo Nordisk A/S Privacy policy Terms of use

change